Analysts Are Bullish on Top Healthcare Stocks: uniQure NV (QURE), Kura Oncology (KURA)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on uniQure NV (QUREResearch Report) and Kura Oncology (KURAResearch Report) with bullish sentiments.

uniQure NV (QURE)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on uniQure NV, with a price target of $73. The company’s shares closed last Monday at $55.59.

Chattopadhyay observed:

“Enrollment completion in the HOPE-B registration study positions 12+month lead. We now anticipate data during 4Q20, with likely commercial launch during 4Q21, ahead of our prior 2H-2022 expectations. We continue to believe, AMT-061 remains the one-and-done therapy of choice based on: (1) the ability to successfully treat subjects with NAB’s to the peer construct; (2) low-levels of NABs to AAV5, which is a significant commercial differentiator, compelling centers to choose a therapy that could benefit the majority of patients i.e., >90% in case of AMT-061, over one with at least 40% exclusion criteria; and (3) no prophylactic steroids.”

According to TipRanks.com, Chattopadhyay has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.3% and a 37.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.

uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $99.40, representing an 84.4% upside. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $175 price target.

See today’s analyst top recommended stocks >>

Kura Oncology (KURA)

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Kura Oncology today. The company’s shares closed last Monday at $15.25.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 3.5% and a 39.3% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

Currently, the analyst consensus on Kura Oncology is a Strong Buy with an average price target of $28.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.